Basic Information

Gene symbol E2F1 Synonyms E2F-1, RBAP1, RBBP3, RBP3 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas | PertOrg
Description E2F transcription factor 1

GTO ID GTC3981
Trial ID NCT04758533
Disease Brain Glioma | Medulloblastoma
Altered gene E2F1
Therapeutic/Target gene Therapeutic gene
TherapyDNA oncolytic virus
Treatment AloCELYVIR
PhasePhase1|Phase2
Recruitment statusActive, Not Recruiting
TitlePhase IB Clinical Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of AloCELYVIR (Mesenchymal Allogenic Cells + ICOVIR-5) in Children, Adolescent and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Relapse/Progression in Monotherapy
Year2021
CountrySpain
Company sponsorHospital Infantil Universitario Niño Jesús, Madrid, Spain
Other ID(s)FIBHNJ-2020-01|2020-004838-37|2022-502516-37-00
Vector information
Vectorhuman mesenchymal stem cells
ConstructAd5-E2F-delta24-RGD
Vector typethird-generation retargeted oncolytic adenovirus
Viral genome modificationTo insert the Kozak sequence before E1A, a KpnI fragment from pShuttle-DM-E2F-Δ-24, containing the E2F promoter and E1A, was subcloned into pGEM-3Z (Promega). This plasmid was then used to replace the E1A translation start site with oligonucleotides containing the Kozak sequence. The KpnI fragment, containing the E2F-E1A modified with the Kozak sequence, was returned to pShuttle-DM-E2F-Δ-24 to generate pShuttle-DM-E2F-KD24. Finally, pShuttle-DM-E2F-Δ-24 was recombined by homologous recombination with pVK503, which contains the complete Ad5 genome with an RGD-modified fiber.
Additional featureMesenchymal allogenic cells

Clinical Result

Cohort 1
Administration route intravenous infusion
Pts 13
Age Child, Adult

Relationship Graph

Overview of Knowledge Graph